Hematologic Response, Free Light Chain Levels May Predict Overall Survival in AL Amyloidosis
AL amyloidosis patients with hematologic response and low serum free light chain levels may have longer OS.
Hematopoietic Stem Cell Transplantation
Gene Expression in Patients With Severe Scleroderma May Predict Stem Cell Transplant Response
Researchers determined whether machine learning could predict stem cell transplant response in severe scleroderma.
Gene-Corrected Hematopoietic Stem Cells Show Potential for Engraftment in Fanconi Anemia
Autologous transplantation with gene-corrected hematopoietic stem cells show engraftment and proliferation in nonconditioned patients with Fanconi anemia.
Outcomes After Daratumumab Addition to Induction Therapy in Newly Diagnosed Multiple Myeloma
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
Glycemic Variability and Pediatric Hematopoietic Stem Cell Transplantation
Glycemic variability is suggested to be a risk factor for complications with hematopoietic stem cell transplantation in pediatric patients.
Personalized Prediction Model for Outcomes After Allogeneic HSCT for Myelodysplastic Syndromes
As transplantation-related complications are high among patients with MDS, determining which patients will benefit from HSCT is essential.
Hemophagocytic Lymphohistiocytosis: Pretransplant Analyses May Prevent Unnecessary HSCT
In a large prospective study, investigators assessed whether pretransplant analyses could prevent unnecessary HSCT in children with HLH.
Relapse Reduction With Sorafenib in FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic HSCT
Researchers assessed the efficacy and safety of sorafenib maintenance among patients with FLT3-ITD AML who underwent allogeneic HSCT.
Sorafenib Maintenance Therapy After Allo-HSCT Improves Outcomes in FLT3-ITD–Positive AML
Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
-
Loading...
-
Loading...
Next post in Leukemia
